From: Galaxy workflows for fragment-based virtual screening: a case study on the SARS-CoV-2 main protease
Index | dcTMD maximum free energy / kJ/mol | Parent (and other component) fragments | Distance of dcTMD maximum from binding site / nm | MMGBSA / kcal/mol | SuCOS | TransFS | Interactions, with occupancy and derived fragment |
---|---|---|---|---|---|---|---|
1 | 22.41 | x0387 (x0434) | 0.45 | \(-\)17.74 | 0.56 | 0.94 | Cys44BO HB 91.5% (x0387) |
Met165 HI 88.5% (x0434) | |||||||
Gln189 HI 94.5% (x0434) | |||||||
His41 pi stacking 6.5% (x0387) | |||||||
2 | 18.4 | x0387 (x0434) | 0.34 | \(-\)25.51 | 0.54 | 0.95 | Met165 HI 94% (x0434) |
His41 pi stacking 44% (x0387) | |||||||
Gln189 HI 88% (x0434) | |||||||
3 | 16.45 | x0991 (x0946) | 0.24 | \(-\)29.93 | 0.64 | 0.96 | |
4 | 15.25 | x0397 | 0.24 | \(-\)31.97 | 0.65 | 0 | Gly143BN HB 100% (x0397) |
Cys145BN HB 83.5% (x0397) | |||||||
Thr25 HI 10.5% (x0397) | |||||||
5 | 14.57 | x0397 | 0.18 | \(-\)30.74 | 0.61 | 0 | Gly143BN HB 85.5% (x0397) |
Cys145BN HB 89.5% (x0397) | |||||||
Thr25 HI 62.5% (x0397) | |||||||
6 | 13.89 | x0434 | 0.38 | \(-\)25.42 | 0.49 | 0.65 | Glu166BN HB 84.5% (x0434) |
Met165 HI 64% (x0434) | |||||||
Gln189 HI 19% (x0434) | |||||||
7 | 13.61 | x0678 | 0.73 | \(-\)26.4 | 0.53 | 0.94 | His163SC HB 14% (x0678) |
Met165 HI 50% (x0678) | |||||||
Glu166 HI 90% (x0678) | |||||||
8 | 11.96 | x0305 | 0.52 | \(-\)25.07 | 0.54 | 0.94 | Met165 HI 87.5% (x0305) |
Gln189SC HB 13% (x0305) | |||||||
9 | 10.95 | x0434 | 0.43 | \(-\)22.71 | 0.52 | 0.68 | Gln189 HI 50.5% (x0434) |
Met165 HI 10.5% (x0434) | |||||||
Glu166BN HB 3.5% (x0434) | |||||||
10 | 10.57 | x0434 (x0387) | 0.29 | \(-\)34.78 | 0.52 | 0.77 | Glu166BN HB 77.5% (x0434) |
Met165 HI 61.5% (x0434) | |||||||
His163SC HB: 44% (x0434) |